Can You Take Abrocitinib and Fluconazole Together?

No. According to U.S. FDA-derived drug safety information, abrocitinib and fluconazole together is contraindicated, meaning the combination should be avoided. When fluconazole is present in your body, it slows down the breakdown of abrocitinib, causing the drug to build up to unsafe levels in your bloodstream. This article explains what that means, why it happens, and what to discuss with your doctor or pharmacist if you take or need either of these medications.

What the Source Says

The interaction record that informs this article comes from U.S. FDA drug labeling via the NIH/NLM RxNorm database. Here is what that source documents:

• Severity: Contraindicated (the highest level of warning for a drug pair)
• Key finding: "Concomitant use increases systemic exposure of abrocitinib and active metabolites due to fluconazole's inhibition of CYP2C19, CYP2C9, and CYP3A4. Avoid concomitant use."
• Mechanism: Fluconazole acts as a strong inhibitor of the CYP2C19 enzyme and a moderate inhibitor of the CYP2C9 and CYP3A4 enzymes.
• Recommendation: The FDA source directs healthcare providers and patients to avoid using these drugs together.

This designation as "contraindicated" is the most serious interaction warning short of an absolute prohibition. It signals that the known or potential harms of the combination outweigh the benefits in routine clinical practice.

How to Understand This

What Are Enzymes and Why Do They Matter?

Your liver and other organs use specialized proteins called enzymes to break down drugs. One family of these enzymes, known as the cytochrome P450 (or CYP450) system, handles the breakdown of thousands of medications. Each enzyme in this family has a number and letter code. The three enzymes mentioned in this interaction—CYP2C19, CYP2C9, and CYP3A4—are three of the most active drug-processing enzymes in your body.

What abrocitinib does: Abrocitinib is a JAK inhibitor, a type of medicine used to treat atopic dermatitis (eczema). Your body breaks it down primarily through the CYP2C19 enzyme, with smaller contributions from CYP2C9 and CYP3A4. After the first dose, abrocitinib is converted into active metabolites—chemical forms that still have biological activity in your body.

What fluconazole does: Fluconazole is an antifungal medication used to treat fungal infections. One of its properties is that it blocks, or inhibits, several of the CYP450 enzymes. The FDA source specifies that fluconazole strongly inhibits CYP2C19 and moderately inhibits both CYP2C9 and CYP3A4.

The Documented Mechanism: Enzyme Inhibition and Drug Buildup

When fluconazole is in your bloodstream, it occupies and blocks the CYP2C19 enzyme—the primary pathway for breaking down abrocitinib. This is like putting a traffic jam at the main exit off a highway. The result is that abrocitinib and its active metabolites accumulate in your system faster than your body can eliminate them. The FDA source document calls this increased "systemic exposure." Higher levels of abrocitinib in your blood increase the risk of unwanted side effects.

Fluconazole's inhibition of CYP2C9 and CYP3A4 is moderate rather than strong, but these pathways also contribute to abrocitinib metabolism. Together, the three-enzyme blockade creates a substantial reduction in how quickly your body can clear the drug.

Why "Systemic Exposure" Matters

Systemic exposure refers to how much of a drug (and its active forms) circulates throughout your entire body and how long it stays there. If abrocitinib exposure increases beyond what clinical trials tested and approved, you face a higher risk of adverse effects—the unwanted or harmful reactions a drug can cause. Because abrocitinib is an immunosuppressive medication (it dampens immune responses), excessive levels may increase risks such as infections or other immune-related problems.

Who Should Pay Particular Attention

This contraindication applies to anyone prescribed or considering both abrocitinib and fluconazole. There are no subgroups identified in the source record as exempt from this warning. However, certain situations warrant extra vigilance:

• If you are starting abrocitinib and are currently taking fluconazole for a fungal infection
• If you are taking abrocitinib and develop a fungal infection that your doctor wants to treat with fluconazole
• If you take abrocitinib regularly and a healthcare provider prescribes fluconazole without knowing about your abrocitinib use
• If you buy fluconazole over-the-counter (it is available without a prescription in many settings) while on abrocitinib

The most common scenario is a patient with atopic dermatitis (already on abrocitinib) who develops a fungal skin infection and is offered fluconazole. This is a situation where close coordination between your dermatologist and the provider prescribing the antifungal is essential.

Hypothetical Example 1: A Patient on Abrocitinib Develops Athlete's Foot

Imagine you have been taking abrocitinib for atopic dermatitis for six months and your eczema is well controlled. You develop athlete's foot (a common fungal infection). Your primary care doctor offers to prescribe fluconazole—a widely used, effective antifungal. You might assume it is safe because both drugs are approved and commonly prescribed. However, because you are already on abrocitinib, using fluconazole would trigger the documented enzyme-blocking interaction. Your body would not clear the abrocitinib as efficiently, and levels could rise. This is why the FDA source says to avoid this combination. Instead, your doctor might choose a different antifungal that does not interact with abrocitinib, or delay the antifungal until you stop abrocitinib (if medically appropriate).

Hypothetical Example 2: A Patient Switches from Fluconazole to Abrocitinib

Now imagine a different scenario: you are taking fluconazole for a vaginal yeast infection and finish your course of treatment. A month later, your dermatologist diagnoses atopic dermatitis and prescribes abrocitinib. Once fluconazole has been completely cleared from your body (typically within days, depending on the dose), the contraindication no longer applies, and starting abrocitinib becomes safe. However, if abrocitinib were started while fluconazole is still in your system—even at the end of a standard course—the interaction risk remains. This is why timing and communication with all your healthcare providers matter.

What to Discuss With a Pharmacist or Physician

If you take abrocitinib or are about to start it, and you also need treatment for a fungal infection, here are key questions to raise with your pharmacist or doctor:

• "I am on abrocitinib for my eczema. I have been offered fluconazole for a fungal infection. I understand these two drugs cannot be used together—is that correct, and what are my alternatives?" This confirms that your healthcare provider is aware of both medications and prompts discussion of safer options.
• "Are there other antifungal medications I can use instead of fluconazole while I remain on abrocitinib?" Depending on the type and location of the fungal infection, alternatives may exist (e.g., topical antifungals, other oral antifungals with different mechanisms). Your doctor or pharmacist can assess which is appropriate for your situation.
• "If I need fluconazole and stopping abrocitinib temporarily is medically acceptable, how long would I need to be off abrocitinib before starting fluconazole, and how long after finishing fluconazole before restarting abrocitinib?" This is a clinical question only a physician can answer, because it depends on your condition, abrocitinib dosing, and the urgency of the fungal infection treatment. It is not a routine scenario, but it is worth understanding if your situation is complex.
• "Does any over-the-counter antifungal I might be tempted to use also interact with abrocitinib?" Some OTC options are safer; others are not. Ask before buying.
• "If I am prescribed a new medication, will the pharmacy check it against abrocitinib?" This is a good time to reinforce that your pharmacist should always review your full medication list for interactions.

Do not adjust your abrocitinib or fluconazole doses or stop either medication on your own. These are decisions that must be made by your prescribing physician in consultation with your pharmacist, based on your full medical picture.

Key Takeaways

• Abrocitinib and fluconazole are contraindicated according to FDA-sourced drug safety information, meaning they should not be used together.
• The interaction occurs because fluconazole inhibits three key liver enzymes (CYP2C19, CYP2C9, and CYP3A4) that break down abrocitinib, causing the drug to accumulate in your bloodstream.
• Increased levels of abrocitinib carry a higher risk of side effects and may reduce the drug's safety profile.
• If you need an antifungal while on abrocitinib, discuss alternatives with your doctor or pharmacist before accepting a fluconazole prescription.
• Always inform every healthcare provider about all medications you take, including over-the-counter drugs and supplements, to catch potential interactions before they occur.

Sources

• U.S. FDA Open Data Portal – Source for FDA drug labeling and safety information
• NIH/NLM RxNorm Database – Normalized drug naming and interaction data
• DailyMed (NLM) – Full FDA-approved drug labeling texts
• PubMed Central – Peer-reviewed literature on drug metabolism and CYP450 interactions

Your medication safety starts with knowledge and clear communication. If you are taking abrocitinib, fluconazole, or both, check your complete medication list at checkdruginteractions.com to see all documented interactions and get up-to-date safety information sourced from the FDA and NIH. Always confirm any changes to your medications—whether stopping, starting, or switching—with a licensed pharmacist or physician who knows your full medical history. This article explains what the evidence says; your healthcare team makes the clinical decision that is right for you.